FAQ: Calidi Biotherapeutics' $6.9 Million Public Offering and Company Overview

What is the main announcement in this content?

Calidi Biotherapeutics has closed a $6.9 million underwritten public offering, including the full exercise of the underwriters’ over-allotment option, with gross proceeds before deducting commissions and expenses.

How much money did Calidi Biotherapeutics raise in this offering?

The company raised gross proceeds of $6.9 million before deducting commissions and expenses from the sale of common stock units and pre-funded warrant units.

What types of securities were sold in this offering?

The company sold 1,922,764 common stock units (each with one share and one Series I warrant) and 1,528,000 pre-funded warrant units (each with one pre-funded warrant and one Series I warrant), including 450,000 common stock units under the over-allotment option.

What are the pricing details for the securities offered?

Common Stock Units were priced at $2.00 each, while Pre-Funded Units were priced at $1.999 each, with Series I warrants exercisable immediately at $2.00 per share and expiring five years from issuance.

Who managed this public offering for Calidi Biotherapeutics?

Ladenburg Thalmann & Co. Inc. acted as sole book-running manager, with Laidlaw & Company (U.K.) Ltd. serving as co-manager for the offering.

What does Calidi Biotherapeutics develop?

Calidi is a clinical-stage immuno-oncology company developing targeted therapies to deliver genetic medicines to distal sites of disease using its proprietary Redtail platform featuring engineered enveloped oncolytic viruses.

What is Calidi’s lead candidate targeting?

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need.

Where can investors find more information about Calidi Biotherapeutics?

The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI, and the full press release can be viewed at https://ibn.fm/FEy8z.

What is TinyGems and its role in this content?

TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio at IBN that provides wire solutions, editorial syndication, and social media distribution services.